



# SARCLISA<sup>®</sup>

## (isatuximab-irfc)

Sarclisa is a novel monoclonal antibody directed against the CD38 receptor on the surface of myeloma cells. This is described as a targeted anti-myeloma therapy. Sarclisa both kills myeloma cells directly and recruits surrounding immune cells to enhance the killing process.

### Approved indication for Sarclisa

The US Food and Drug Administration (FDA) approved Sarclisa in combination with the immunomodulatory drug Pomalyst<sup>®</sup> (pomalidomide) and the steroid dexamethasone (Isa-Pd) for patients with relapsed refractory myeloma who have received Revlimid<sup>®</sup> (lenalidomide) and a proteasome inhibitor (such as Velcade<sup>®</sup>, Ninlaro<sup>®</sup>, or Kyprolis<sup>®</sup>).

### Dose and schedule for Isa-Pd

- **Sarclisa** is given as an intravenous infusion at a dose of 10 mg/kg every week for 4 weeks, then every 2 weeks. The first and second infusions take about 3–4 hours, but the remaining infusions are typically 75 minutes.
- **Pomalyst** is taken by mouth in capsule form, 4 mg on days 1–21 of every 28-day cycle.
- **Dexamethasone** can be taken by mouth in tablet form or as an intravenous infusion, 40 mg once weekly, and for patients over 75 years of age, 20 mg once weekly.

*(continues on reverse side)*

## Possible side effects of Isa-Pd

The most common side effects (occurring in  $\geq 20\%$  of patients) include the following:

- **Neutropenia:** Your white blood cell count and percentage of neutrophils will be monitored to make sure the number of neutrophils does not drop too low.
- **Upper respiratory tract infection and pneumonia:** Be alert for any fever, cough, or flu-like symptoms. Contact your doctor immediately if concerned.
- **Infusion reactions:** Medications are given before and during Sarclisa infusions to minimize the risk of infusion reactions.
- **Diarrhea:** Be sure to drink a sufficient amount of water and contact your doctor if you experience dizziness, light-headedness, and/or fainting.

## Access and support resources

To explore the access and support resources for Sarclisa that may be available for eligible patients, please call **1.833.930.2273** or visit **[SanofiCareAssist.com/Sarclisa](https://SanofiCareAssist.com/Sarclisa)**.

*As always, the IMF urges you to discuss all medical issues with your doctor, and to contact the IMF with your myeloma questions and concerns.*



**INTERNATIONAL  
MYELOMA  
FOUNDATION**

## International Myeloma Foundation

12650 Riverside Drive, Suite 206, North Hollywood, CA 91607 USA

818.487.7455 800.452.CURE [myeloma.org](https://myeloma.org)

Improving Lives **Finding the Cure**<sup>®</sup>